The effect of risk factor changes on peripheral arterial disease and cardiovascular risk

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 4, Issue 3, 2004, Pages 259-263

  Mohler III, Emile R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; AZITHROMYCIN; BETA CAROTENE; COLESTIPOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

APHERESIS; ARTERY DISEASE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHLAMYDIASIS; CLAUDICATION; CLINICAL TRIAL; DIABETES MELLITUS; DIET THERAPY; DRUG MECHANISM; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PERIPHERAL VASCULAR DISEASE; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; STROKE; VASCULAR DISEASE;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DISEASE PROGRESSION; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INFECTION; PERIPHERAL VASCULAR DISEASES; RISK FACTORS;

EID: 4444286495     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568006043335998     Document Type: Review

References (65)

1. Hirsch, A.T., Criqui, M.H., Treat-Jacobson, D., Regensteiner, J.G., Creager, M.A., Olin, J.W., Krook, S.H., Hunninghake, D.B., Comerota, A.J., Walsh, M.E., McDermott, M.M., Hiatt, W.R. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA, 2001, 286(11), 1317-1324.
2. Belch, J.J., Topol, E.J., Agnelli, G., Bertrand, M., Califf, R.M., Clement, D.L., Creager, M.A., Easton, J.D., Gavin, J.R. III, Greenland, P., Hankey, G., Hanrath, P., Hirsch, A.T., Meyer, J., Smith, S.C., Sullivan, F., Weber, M.A. Critical issues in peripheral arterial disease detection and management: a call to action. Arch. Intern. Med., 2003, 163(8), 884-892.
3. Mukherjee, D., Lingam, P., Chetcuti, S., Grossman, P.M., Moscucci, M., Luciano, A.E., Eagle, K.A. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-Q12). Circ., 2002, 106(15), 1909-1912.
4. Criqui, M.H., Langer, R.D., Fronek, A., Feigelson, H.S., Klauber, M.R., McCann, T.J., Browner, D. Mortality over a period of 10 years in patients with peripheral arterial disease. N. Engl. J. Med., 1992, 326(6), 381-386.
5. Fowkes, F.G. Epidemiological research on peripheral vascular disease. J. Clin. Epidemiol., 2001, 54(9), 863-868.
6. Hertzer, N.R., Beven, E.G., Young, J.R., O'Hara, P.J., Ruschhaupt, W.F. III, Graor, R.A., de Wolfe, V.G., Maljovec, L.C. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann. Surg., 1984, 199(2), 223-233.
7. Fowkes, F.G., Housley, E., Riemersma, R.A., Macintyre, C.C., Cawood, E.H., Prescott, R.J., Ruckley, C.V. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am. J. Epidemiol., 1992, 135(4), 331-340.
8. Schainfeld, R.M. Management of peripheral arterial disease and intermittent claudication. J. Am. Board Fam. Pract., 2001, 14(6), 443-450.
9. Erb, W. Beiträge zur Pathologie des intermittierenden Hinkens. Münch Med. Wschr., 1911, 2, 2487.
10. Hughson, W.G., Mann, J.I., Garrod, A. Intermittent claudication: prevalence and risk factors. Br. Med. J., 1978, 1(6124), 1379-1381.
11. Reunanen, A., Takkunen, H., Aromaa, A. Prevalence of intermittent claudication and its effect on mortality. Acta Med. Scand, 1982, 211(4), 249-256.
12. Kannel, W.B., McGee, D.L. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J. Am. Geriatr. Soc., 1985, 33(1), 13-18.
13. Gofin, R., Kark, J.D., Friedlander, Y., Lewis, B.S., Witt, H., Stein, Y., Gotsman, M.S. Peripheral vascular disease in a middle-aged population sample. The Jerusalem Lipid Research Clinic Prevalence Study. Isr. J. Med. Sci., 1987, 23(3), 157-167.
14. Murabito, J.M., D'Agostino, R.B., Silbershatz, H., Wilson, W.F. Intermittent claudication. A risk profile from The Framingham Heart Study. Circ., 1997, 96, 44-49.
15. Kannel, W.B. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J. Cardiovasc. Risk., 1994, 1(4), 333-339.
16. Criqui, M.H., Browner, D., Fronek, A., Klauber, M.R., Coughlin, S.S., Barrett-Connor, E., Gabriel, S. Peripheral arterial disease in large vessels is epidemiologically distinct from small vessel disease. An analysis of risk factors. Am. J. Epidemiol., 1989, 129(6), 1110-1119.
17. Gordon, T., Kannel, W.B. Predisposition to atherosclerosis in the head, heart, and legs. The Framingham study. JAMA, 1972, 221(7), 661-666.
18. Freund, K.M., Belanger, A.J., D'Agostino, R.B., Kannel, W.B. The health risks of smoking. The Framingham Study: 34 years of follow- up. Ann. Epidemiol., 1993, 3(4), 417-424.
19. Ingolfsson, I.O., Sigurdsson, G., Sigvaldason, H., Thorgeirsson, G., Sigfusson, N. A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol - the Reykjavik Study. J. Clin. Epidemiol., 1994, 47(11), 1237-1243.
20. Weiss, N.S. Cigarette smoking and arteriosclerosis obliterans: an epidemiologic approach. Am. J. Epidemiol., 1972, 95(1), 17-25.
21. Powell, J.T., Edwards, R.J., Worrell, P.C., Franks, P.J., Greenhalgh, R.M., Poulter, N.R. Risk factors associated with the development of peripheral arterial disease in smokers: a case-control study. Athero., 1997, 129(1), 41-48.
22. Quick, C.R., Cotton, L.T. The measured effect of stopping smoking on intermittent claudication. Br. J. Surg., 1982, 69 Suppl., S 24-S26.
23. Jonason, T., Bergstrom, R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med. Scand, 1987, 221, 253-260.
24. Ameli, F.M., Stein, M., Provan, J.L., Prosser, R. The effect of postoperative smoking on femoropopliteal bypass grafts. Ann. Vasc. Surg., 1989, 3, 20-25.
25. Beach, K.W., Brunzell, J.D., Strandness, D.E., Jr. Prevalence of severe arteriosclerosis obliterans in patients with diabetes mellitus. Relation to smoking and form of therapy. Arteriosclerosis, 1982, 2(4), 275-280.
26. Beks, P.J., Mackaay, A.J., de Neeling, J.N., de Vries, H., Bouter, L.M., Heine, R.J. Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: the Hoorn study. Diabetologia, 1995, 38(1), 86-96.
27. Jude, E.B., Oyibo, S.O., Chalmers, N., Boulton, A.J. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care, 2001, 24(8), 1433-1437.
28. Beckman, J.A., Creager, M.A., Libby, P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA, 2002, 287(19), 2570-2581.
29. UK Prospective Diabetes Study Group. The UK Prospective Diabetes Study. Lancet, 1998, 35, 837-853.
30. Perkins, B.A., Ficociello, L.H., Silva, K.H., Finkelstein, D.M., Warram, J.H., Krolewski, A.S. Regression of microalbuminuria in type 1 diabetes. N. Engl. J. Med., 2003, 348(23), 2285-2293.
31. Nathan, D.M., Lachin, J., Cleary, P., Orchard, T., Brillon, D.J., Backlund, J.Y., O'Leary, D.H., Genuth, S. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N. Engl. J. Med., 2003, 348(23), 2294-2303.
32. Bowlin, S.J., Medalie, J.H., Flocke, S.A., Zyzanski, S.J., Goldbourt, U. Epidemiology of intermittent claudication in middle-aged men. Am. J. Epidemiol., 1994, 140(5), 418-430.
33. Cantin, B., Moorjani, S., Dagenais, G.R., Lupien, P.J. Lipoprotein(a) distribution in a French Canadian population and its relation to intermittent claudication (the Quebec Cardiovascular Study). Am. J. Cardiol., 1995, 75, 1224-1228.
34. Johansson, J., Egberg, N., Johnsson, H., Carlson, L.A. Serum lipoproteins and hemostatic function in intermittent claudication. Arterioscler Thromb., 1993, 13(10), 1441-1448.
35. Hiatt, W.R., Hoag, S., Hamman, R.F. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circ., 1995, 91(5), 1472-1479.
36. Joensuu, T., Salonen, R., Winblad, I., Korpela, H., Salonen, J.T. Determinants of femoral and carotid artery atherosclerosis. J. Intern. Med., 1994, 236(1), 79-84.
37. Gariepy, J., Simon, A., Massonneau, M., Linhart, A., Levenson, J. Wall thickening of carotid and femoral arteries in male subjects with isolated hypercholesterolemia. PCVMETRA Group. Prevention Cardio-Vasculaire en Medecine du Travail. Athero., 1995, 113(2), 141-151.
38. Mowat, B.F., Skinner, E.R., Wilson, H.M., Leng, G.C., Fowkes, F.G., Horrobin, D. Alterations in plasma lipids, lipoproteins and high density lipoprotein subtractions in peripheral arterial disease. Athero., 1997, 13(2), 161-166.
39. Blankenhorn, D.H., Azen, S.P., Crawford, D.W., Nessim, S.A., Sanmarco, M.E., Selzer, R.H., Shircore, A.M., Wickham, E.C. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation, 1991, 83, 438-447.
40. De Groot, E., Jukema, J.W., Montauban van Swijndregt, A.D., Zwinderman, A.H., Ackerstaff, R.G., van der Steen, A.F. et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J. Am. Coll. Cardiol., 1998, 31(7), 1561-1567.
41. Pedersen, T.R., Kjekshus, J., Pyorala, K., Olsson, A.G., Cook, T.J., Musliner, T.A., Tobert, J.A., Haghfelt, T. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am. J. Cardiol., 1998, 81, 333-335.
42. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360(9326), 7-22.
43. Mondillo, S., Ballo, P., Barbati, R., Guerrini, F., Ammaturo, T., Agricola, E., Pastore M., Borrello, F., Belcastro, M., Picchi, A., Nami, R. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am. J. Med., 2003, 114(5), 359-364.
44. Aronow, W.S., Nayak, D., Woodworth, S., Ahn, C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am. J. Cardiol., 2003, 92(6), 711-712.
45. Mohler, E.R., Hiatt, W.R., Creager, M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral vascular disease. Circulation, 2003, 108(12), 1481-1486.
46. Kroon, A.A., van Asten, W.N., Stalenhoef, A.F. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann. Intern. Med., 1996, 125(12), 945-954.
47. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001, 285(19), 2486-2497.
48. Schmidt-Ott, K.M., Kagiyama, S., Phillips, M.I. The multiple actions of angiotensin II in atherosclerosis. Regul. Pept., 2000, 93(1-3), 65-77.
49. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., Dagenais, G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med., 2000, 342(3), 145-153.
50. UK Prospective Diabetes Study Group. UKPDS Blood Pressure Study. British Medical Journal, 1998, 317, 703-713.
51. Ridker, P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circ., 2003, 107(3), 363-369.
52. Ridker, P.M., Stampfer, M.J., Rifai, N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA, 2001, 285(19), 2481-2485.
53. Graham, I.M., Daly, L.E., Refsum, H.M., Robinson, K., Brattstrom, L.E., Ueland, P.M., Palma-Reis, R.J., Boers, G.H., Sheahan, R.G., Israelsson, B., Uiterwaal, C.S., Meleady, R., McMaster, D., Verhoef, P., Witteman, J., Rubba, P., Bellet H, Wautrecht JC, de Valk HW, Sales Luis A,C., Parrot-Rouland, F.M., Tan, K.S., Higgins, I., Garcon, D., Andria, G., et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA, 1997, 277(22), 1775-1781.
54. Malinow, M.R., Kang, S.S., Taylor, L.M., Wong, P.W., Coull, B., Inahara, T., Mukerjee, D., Sexton, G., Upson, B. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circ., 1989, 79(6), 1180-1188.
55. Kang, S.S., Wong, P.W., Malinow, M.R. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu. Rev. Nutr., 1992, 12, 279-298.
56. Fermo, I., Vigano, D.S., Paroni, R., Mazzola, G., Calori, G., D'Angelo, A. Prevalence of moderate hyperhomocysteinemia in patients with early- onset venous and arterial occlusive disease. Ann. Intern. Med., 1995, 123(10), 747-753.
57. Welch, G.N., Loscalzo, J. Homocysteine and atherothrombosis. N. Engl. J. Med., 1998, 338(15), 1042-1050.
58. Blann, A.D., Gurney, D., Hughes, E., Buggins, P., Silverman, S.H., Lip, G.Y. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. Am. J. Cardiol., 2001, 88(1), A7-92.
59. Vaughan, D.E. Plasminogen Activator Inhibitor 1: Molecular Aspects and Clinical Importance. J. Thromb. Thrombolysis, 1995, 2(3), 187-193.
60. Bazzano, L.A., He, J., Muntner, P., Vupputuri, S., Whelton, P.K. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann. Intern. Med., 2003, 138(11), 891-897.
61. Muhlestein, I.B., Anderson, J.L., Hammond, E.H., Zhao, L., Trehan, S., Schwobe, E.P., Carlquist, J.F. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circ., 1998, 97(7), 633-636.
62. Muhlestein, J.B. Chronic infection and coronary artery disease. Med. Clin. North Am., 2000, 84(1), 123-148.
63. Gupta, S., Leatham, E.W., Carrington, D., Mendall, M.A., Kaski, J.C., Camm, A.J. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circ., 1997, 96(2), 404-407.
64. Gurfinkel, E., Bozovich, G., Daroca, A., Beck, E., Mautner, B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet, 1997, 350(9075), 404-407.
65. Anderson, J.L., Muhlestein, J.B. The ACADEMIC study in perspective (Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia). J. Infect Dis., 2000, 181 Suppl. 3, S569-S571.